HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer

[1]  Henry W. Long,et al.  Prostate cancer reactivates developmental epigenomic programs during metastatic progression , 2020, Nature Genetics.

[2]  R. Bhanvadia,et al.  MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans , 2020, eLife.

[3]  Luke A. Gilbert,et al.  DNA methylation landscapes in advanced prostate cancer , 2020, Nature Genetics.

[4]  Chunlai Lu,et al.  The SMART App: an interactive web application for comprehensive DNA methylation analysis and visualization , 2019, Epigenetics & Chromatin.

[5]  Takafumi N. Yamaguchi,et al.  Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors. , 2019, Cancer cell.

[6]  Jacob D. Jaffe,et al.  High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program , 2019, Nature Communications.

[7]  S. Bratman,et al.  Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA , 2019, Nature Protocols.

[8]  Jindan Yu,et al.  Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression , 2019, Cell Research.

[9]  G. Leone,et al.  The broken cycle: E2F dysfunction in cancer , 2019, Nature Reviews Cancer.

[10]  M. Rubin,et al.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. , 2019, Cancer cell.

[11]  W. Isaacs,et al.  HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer , 2018, The Prostate.

[12]  D. Nomura,et al.  Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer , 2019, Science Translational Medicine.

[13]  Ximing J. Yang,et al.  Targeting FOXA1-mediated repression of TGF-&bgr; signaling suppresses castration-resistant prostate cancer progression , 2018, The Journal of clinical investigation.

[14]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[15]  Ximing J. Yang,et al.  Targeting FOXA 1-mediated repression of TGF-b signaling suppresses castration-resistant prostate cancer progression , 2019 .

[16]  M. Loda,et al.  Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer , 2018, Proceedings of the National Academy of Sciences.

[17]  Jindan Yu,et al.  TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression , 2018, Nature Communications.

[18]  M. Lazar,et al.  Integrative regulation of physiology by histone deacetylase 3 , 2018, Nature Reviews Molecular Cell Biology.

[19]  Zhihua Liu,et al.  Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 , 2018, Proceedings of the National Academy of Sciences.

[20]  H. He,et al.  Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer , 2017, Oncogene.

[21]  I. Mills,et al.  Genetics of lipid metabolism in prostate cancer , 2018, Nature Genetics.

[22]  J. Clohessy,et al.  An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer , 2018, Nature Genetics.

[23]  A. Cavalli,et al.  Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer , 2017, Nature Genetics.

[24]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[25]  P. Nelson,et al.  LuCaP Prostate Cancer Patient‐Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics , 2017, The Prostate.

[26]  Richard Ventura,et al.  FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression , 2016, EBioMedicine.

[27]  Wei Li,et al.  DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A , 2016, Genome Biology.

[28]  L. Butler,et al.  Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. , 2016, Endocrine-related cancer.

[29]  J. Lindberg,et al.  Gene regulatory mechanisms underpinning prostate cancer susceptibility , 2016, Nature Genetics.

[30]  Z. Szallasi,et al.  CAUSEL: An epigenome and genome editing pipeline for establishing function of non-coding GWAS variants , 2015, Nature Medicine.

[31]  Henry W. Long,et al.  The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.

[32]  Richard Ventura,et al.  Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression , 2015, EBioMedicine.

[33]  M. Peinado,et al.  Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer , 2015, Epigenetics & Chromatin.

[34]  R. Zare,et al.  MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism , 2015, Proceedings of the National Academy of Sciences.

[35]  R. Eeles,et al.  Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Ji-Xin Cheng,et al.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. , 2014, Cell metabolism.

[37]  Kai Zhang,et al.  A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding , 2014, Nature Genetics.

[38]  Kyoung-Jae Won,et al.  Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. , 2013, Molecular cell.

[39]  Serena G. Liao,et al.  Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. , 2013, The American journal of pathology.

[40]  Hanfei Sun,et al.  Target analysis by integration of transcriptome and ChIP-seq data with BETA , 2013, Nature Protocols.

[41]  Howard Y. Chang,et al.  Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.

[42]  Jindan Yu,et al.  Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. , 2013, Cancer research.

[43]  Kyoung-Jae Won,et al.  Nuclear Receptor Corepressors are Required for the Histone Deacetylase Activity of HDAC3 In Vivo , 2012, Nature Structural &Molecular Biology.

[44]  Ranjana Mitra,et al.  Detection of Lipid-Rich Prostate Circulating Tumour Cells with Coherent Anti-Stokes Raman Scattering Microscopy , 2012, BMC Cancer.

[45]  Edwin Cheung,et al.  A transcriptional repressor co‐regulatory network governing androgen response in prostate cancers , 2012, The EMBO journal.

[46]  Hong Wang,et al.  Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration , 2012, Nature Medicine.

[47]  Sohaib A. Khan,et al.  Regulated Clearance of Histone Deacetylase 3 Protects Independent Formation of Nuclear Receptor Corepressor Complexes* , 2012, The Journal of Biological Chemistry.

[48]  J. Carpten,et al.  Germline mutations in HOXB13 and prostate-cancer risk. , 2012, The New England journal of medicine.

[49]  T. Ushijima,et al.  Effects of genome architecture and epigenetic factors on susceptibility of promoter CpG islands to aberrant DNA methylation induction. , 2011, Genomics.

[50]  Tao Liu,et al.  A Circadian Rhythm Orchestrated by Histone Deacetylase 3 Controls Hepatic Lipid Metabolism , 2011, Science.

[51]  D. McDonnell,et al.  The homeodomain protein HOXB13 regulates the cellular response to androgens. , 2009, Molecular cell.

[52]  Dustin E. Schones,et al.  Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive Genes , 2009, Cell.

[53]  Sanjay Gupta,et al.  The role of histone deacetylases in prostate cancer , 2008, Epigenetics.

[54]  Daniel E. Newburger,et al.  Variation in Homeodomain DNA Binding Revealed by High-Resolution Analysis of Sequence Preferences , 2008, Cell.

[55]  S. Hiebert,et al.  Liver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks , 2008, The EMBO journal.

[56]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[57]  M. Washburn,et al.  Quantitative proteomic analysis of distinct mammalian Mediator complexes using normalized spectral abundance factors , 2006, Proceedings of the National Academy of Sciences.

[58]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.

[59]  S. Balk,et al.  The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists* , 2005, Journal of Biological Chemistry.

[60]  C. Cooper,et al.  Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer , 2004, British Journal of Cancer.

[61]  C. Jung,et al.  HOXB13 Induces Growth Suppression of Prostate Cancer Cells as a Repressor of Hormone-Activated Androgen Receptor Signaling , 2004, Cancer Research.

[62]  M. Capecchi,et al.  Hoxb13 is required for normal differentiation and secretory function of the ventral prostate , 2003, Development.

[63]  Y. Shang,et al.  Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[64]  M. Guenther,et al.  The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3 , 2001, Molecular and Cellular Biology.

[65]  J. Qin,et al.  Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3 , 2000, The EMBO journal.

[66]  C. Bieberich,et al.  Androgen‐independent expression of hoxb‐13 in the mouse prostate , 1999, The Prostate.

[67]  J. Swinnen,et al.  Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[68]  C. Glass,et al.  A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression , 1997, nature.

[69]  J. Swinnen,et al.  Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. , 1997, Cancer research.

[70]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[71]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.